Efficacy in Myopia Control: The Low-Concentration Atropine for Myopia Progression (LAMP) Study

The 3-year Low-Concentration Atropine for Myopia Progression (LAMP) Study has greatly enhanced knowledge of the use of low-concentration atropine for myopia control. 1 Yam JC Jiang Y Tang SM et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Ophthalmology. 2019; 126: 113-124 Abstract Full Text Full Text PDF PubMed Scopus (267) Google Scholar ,2 Yam JC Zhang XJ Zhang Y et al. Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout: Phase 3 Report. Ophthalmology. 2022; 129: 308-321 Abstract Full Text Full Text PDF Scopus (27) Google Scholar In year 1, children were randomized to receive 0.05%, 0.025%, or 0.01% atropine, or placebo. 1 Yam JC Jiang Y Tang SM et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Ophthalmology. 2019; 126: 113-124 Abstract Full Text Full Text PDF PubMed Scopus (267) Google Scholar Compared to the placebo, axial elongation was slowed 0.21, 0.12, and 0.05 mm by 0.05%, 0.025%, and 0.01% atropine, respectively. Myopia progression showed a corresponding slowing of 0.54, 0.35, and 0.22 D.